- Home
- Publications
- Publication Search
- Publication Details
Title
Precision medicine needs randomized clinical trials
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 5, Pages 317-323
Publisher
Springer Nature
Online
2017-02-07
DOI
10.1038/nrclinonc.2017.8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rare cancers: a sea of opportunity
- (2016) Niki Boyd et al. LANCET ONCOLOGY
- What have we learned from SHIVA?
- (2016) Christophe Le Tourneau et al. Nature Reviews Clinical Oncology
- Adaptive Randomization of Neratinib in Early Breast Cancer
- (2016) John W. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development?
- (2016) David Harrington et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study
- (2016) Mohamed Amine Bayar et al. STATISTICS IN MEDICINE
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials
- (2015) X. Paoletti et al. ANNALS OF ONCOLOGY
- Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
- (2015) M. R. Theoret et al. CLINICAL CANCER RESEARCH
- Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
- (2015) J. R. Sachs et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- The role of nonrandomized trials in the evaluation of oncology drugs
- (2015) R Simon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Commentary on Hey and Kimmelman
- (2015) Marc Buyse Clinical Trials
- Are outcome-adaptive allocation trials ethical?
- (2015) Spencer Phillips Hey et al. Clinical Trials
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
- (2015) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
- (2015) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Expansion platform type II: testing a treatment strategy
- (2015) Daniel V T Catenacci LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 21st Century Cures Act — Will It Take Us Back in Time?
- (2015) Jerry Avorn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
- (2015) Denis L. Fontes Jardim et al. JNCI-Journal of the National Cancer Institute
- Designs of drug-combination phase I trials in oncology: a systematic review of the literature
- (2014) M.- K. Riviere et al. ANNALS OF ONCOLOGY
- Ethical Considerations for Outcome-adaptive Trial Designs: A Clinical Researcher's Perspective
- (2014) Scott Brian Saxman BIOETHICS
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
- (2014) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- Discontinued in 2013: oncology drugs
- (2014) Robert Williams EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Improving the Drug Development Process
- (2014) Benjamin Djulbegovic et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience
- (2014) Suzanne E. Dahlberg et al. JNCI-Journal of the National Cancer Institute
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Determining the optimal dose in the development of anticancer agents
- (2014) Ron H. J. Mathijssen et al. Nature Reviews Clinical Oncology
- Equipoise abandoned? Randomization and clinical trials
- (2013) R. Kurzrock et al. ANNALS OF ONCOLOGY
- Designing Transformative Clinical Trials in the Cancer Genome Era
- (2013) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
- (2013) Arif Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- Formal Statistical Testing and Inference in Randomized Phase II Trials in Medical Oncology
- (2012) Everardo D. Saad et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trials: A Long-term Investment With Promising Returns
- (2011) M. R. Sharma et al. JNCI-Journal of the National Cancer Institute
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Early Accelerated Approval for Highly Targeted Cancer Drugs
- (2011) Bruce A. Chabner NEW ENGLAND JOURNAL OF MEDICINE
- Rethinking Clinical Trials
- (2011) A. Grove SCIENCE
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study
- (2010) P Sanwald-Ducray et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Randomized Phase II Trials: Inevitable or Inadvisable?
- (2010) Hui K. Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
- (2010) Hui Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome-Adaptive Randomization: Is It Useful?
- (2010) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Agile Designs in First-in-Human (FIH) Trials—A Simulation Study
- (2009) Itay Perlstein et al. AAPS Journal
- The Need for Large-Scale Randomized Evidence Without Undue Emphasis on Small Trials, Meta-analyses, or Subgroup Analyses
- (2009) Charles H. Hennekens JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
- (2009) Sumithra J. Mandrekar et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimising the design of phase II oncology trials: The importance of randomisation
- (2008) Mark J. Ratain et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started